Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series on Tuesday, July 28, 2026, at 12 PM EDT. CEO and Chairman Robert Bitterman will present an overview of the company’s proprietary INTASYL® siRNA gene silencing platform, highlighting lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session with investors. This announcement corrects the previously misstated day of the week. A replay may be available on Renmark’s website. Phio describes PH-762, which silences the PD-1 gene, as a potential non-surgical treatment for various skin cancers.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the appointment of R. Todd Plott, M.D., a board-certified dermatologist, researcher, inventor and former FDA advisory committee member, to its Board of Directors. Dr. Plott brings more than 30 years of experience in dermatologic care, clinical research and drug development.
According to Phio, he has overseen hundreds of clinical trials and contributed to advancing treatments for acne and other skin conditions. He is currently in private practice focusing on complex skin diseases, acne and skin cancer. Phio highlighted his expertise as the company advances PH-762 for squamous cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, reported new intellectual property milestones for its INTASYL® gene silencing technology. The company received three patent notices of allowance and one grant decision in the United States, Canada, and Japan, expanding protection of its INTASYL compounds and related innovations.
According to Phio Pharmaceuticals, these actions enhance its global patent portfolio, which now includes 54 issued patents covering INTASYL chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications in key countries, supporting its strategy for partnerships, R&D, and future commercialization.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on Tuesday, June 30, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the INTASYL siRNA platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
According to Phio, PH-762 is an INTASYL compound that silences the PD-1 gene implicated in various skin cancers and has been evaluated in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) will join a live virtual fireside chat hosted by Force Family Office on Monday, June 29, 2026 at 12 PM EDT. CEO Robert Bitterman and Dr. James Cardia will discuss siRNA therapy, skin cancer treatments, and Phio’s INTASYL® immuno-oncology program.
Phio Pharmaceuticals (NASDAQ: PHIO) reported a key milestone for its lead candidate PH-762. Nitto Denko Avecia has begun the first commercial-scale cGMP production of PH-762 drug substance under a services agreement signed in June 2025.
The new supply is intended to support an upcoming clinical trial in the next development phase of Phio's intratumoral program. Phio also recently completed a Phase 1b dose-escalation study of PH-762 for cutaneous carcinomas.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharma company, will participate in the Life Sciences Investor Forum on June 24-25, 2026.
CEO Robert Bitterman will present the INTASYL gene-silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by live Q&A and one-on-one meetings.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ Live Virtual Non-Deal Roadshow Series on Thursday, May 28, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the company’s INTASYL siRNA gene silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
PH-762, which silences the PD-1 gene, is in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) will host a live virtual fireside chat with Force Family Office on May 19, 2026 at 4 PM EDT, focused on innovations in skin cancer treatment and prevention.
Recent highlights include Phase 1b data for PH-762 showing no dose-limiting toxicities or serious adverse events among 22 treated patients, a reported ~65% pathological response rate in cSCC (including 6 of 7 responders in the highest-dose cohort), targeted FDA engagement in Q2 2026, and cash projected to fund operations into the first half of 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q1 2026 results and a business update on May 7, 2026. The company completed its Phase 1b dose‑escalation trial of PH‑762 with favorable safety/pathology signals and targets an FDA submission in Q2 2026 to define next clinical steps.
Key financials: $17M cash at March 31, 2026; net loss of $4.0M for Q1 2026; R&D spend rose 215% YoY. Capital actions include ~$23.7M net proceeds in 2025 and an ATM for up to $6.36M.